# Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

> **NCT02065882** · PHASE3 · COMPLETED · sponsor: **Biotest** · enrollment: 67 (actual)

## Conditions studied

- Congenital Afibrinogenemia
- Congenital Hypofibrinogenemia

## Interventions

- **DRUG:** BT524 (Part I)
- **DRUG:** BT524 (Part II)

## Key facts

- **NCT ID:** NCT02065882
- **Lead sponsor:** Biotest
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2020-05-18
- **Final completion:** 2020-11-18
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065882, "Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02065882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*